Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy
- PMID: 32341524
- PMCID: PMC7184542
- DOI: 10.1038/s41571-020-0375-1
Cancer and COVID-19 - potentially deleterious effects of delaying radiotherapy
Abstract
Radiotherapy can be safely delivered during the coronavirus disease 2019 (COVID-19) pandemic, often through use of hypofractionated regimens, which minimize the number of visits to treatment centres while also avoiding potentially detrimental delays in the delivery of cancer care.
Conflict of interest statement
S.C.F. declares funding for clinical trials from Bristol Myers Squibb, Merck and Varian, speaker and/or advisory honoraria from Astra Zeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serono/Merck, GlaxoSmithKline, Janssen, MedImmune, Merck US, Regeneron, Varian, ViewRay. All interests declared are not directly related to this manuscript. H.N. declares no competing interests.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
